Patients for Affordable Drugs Now Poll Finds Vast Majority of Voters Reject Pharmaceutical Industry Rhetoric, Want Lawmakers to Hold Big Pharma Accountable A new national survey from Patients for Affordable Drugs Now shows the vast majority of American voters continue to support solutions to lower prescription drug prices by holding Big Pharma accountable. The survey […]
J&J Beats Q1 Earnings Expectations, Announces Dividend Increase After Hiking Prices on Dozens of Brand Name Drugs This week, Johnson & Johnson kicked off the first round of Big Pharma earnings reports for the first quarter of 2022. Yet again, the Big Pharma giant surpassed Wall Street analysts’ earnings expectations, growing sales and posting massive […]
Highlights How Administration and Lawmakers Can Fix Loopholes Exploited by Pharmaceutical Companies to Keep Drug Prices High A new editorial from The New York Times Editorial Board highlights how Big Pharma games the system to keep drug prices high and calls for reforms to increase competition and help lower drug prices for the American people. […]
New Report Demonstrates How Brand Name Drug Companies Work in “Lockstep” to Hit Patients with Higher Prices on Life-Saving Medications In case you missed it, a new report this week from Patients for Affordable Drugs (P4AD) looks into the history of two blockbuster blood-thinning medications, Bristol Myers Squibb and Pfizer’s Eliquis and Johnson & Johnson’s […]
Academic Study Underscores How Big Pharma’s Price-Gouging on Treatments for Diseases Like Cancer Drives Crisis of Affordability An academic analysis published this week in Health Affairs examines Medicare enrollees’ habits when prescribed new, high-price specialty drugs for four specific conditions. The analysis compares the difference between the number of prescriptions filled and picked up for […]
Lawmakers Double-Down on Repeated Promises to the American People to Lower Prescription Drug Prices and Crack Down on Brand Name Drug Companies During a hearing Wednesday before the U.S. Senate Committee on Finance, lawmakers on both sides of the aisle emphasized the need for urgent action to lower prescription drug prices by holding Big Pharma […]
Congress Can Refocus Attention on Market-Based Solutions to Crack Down on Brand Name Drug Companies’ Egregious Pricing Practices OPPORTUNITY TO HOLD BIG PHARMA ACCOUNTABLE Lawmakers have an important opportunity this week to refocus attention on the urgent need for market-based solutions to hold Big Pharma accountable and lower prescription drug prices. On Wednesday, March 16, […]
Non-Profit and Private Sector Partners Work Together to Help Provide Relief from Big Pharma’s Insulin Price-Gouging Last week, non-profit Civica Rx and the organization’s private sector partners announced plans to manufacture and sell affordable insulin for no more than $30 per vial — demonstrating how health care leaders can work together to help deliver relief […]
Matrix Global Advisors Report Further Undermines Big Pharma’s Supply Chain Blame Game A new report from Matrix Global Advisors (MGA), “Understanding Drug Rebates and Their Role in Promoting Competition,” finds price trends for rebated and non-rebated drugs were similar over the last four years – further undercutting the repeatedly debunked rhetoric from Big Pharma that […]
KFF Analysis Shows Big Pharma’s Price Hikes Outpaced Inflation for Half of All Prescription Drugs Covered by Medicare A new analysis from the Kaiser Family Foundation (KFF) found Big Pharma hiked prices faster than the rate of inflation on 23 of the top 25 most popular prescription drugs in the Medicare Part D program in […]